Celgene Corp. buy tamam
Start price
19.03.17
/
50%
€113.26
Target price
12.11.18
€127.22
Performance (%)
-41.19%
End price
12.11.18
€66.61
Summary
This prediction ended on 12.11.18 with a price of €66.61. Massive losses of -41.19% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | 1.001% | -1.218% | 13.263% | 60.023% |
| iShares Nasdaq 100 | -1.447% | -4.597% | 0.414% | 85.321% |
| iShares Nikkei 225® | 8.406% | 8.425% | 27.328% | 61.038% |
| iShares S&P 500 | -0.226% | -2.451% | 0.167% | 57.738% |
Comments by tamam for this prediction
In the thread Celgene Corp. diskutieren
Celgene is a true "buy & hold" name in the biotech sector
tamam stimmt am 19.03.2017 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 141.04$ zu.
(Vom Mitglied beendet)